Skip to main content

Advertisement

Table 9 One-way sensitivity analysis results for genotype 1 comparing peginterferon-alfa-2a to peginterferon-alfa-2b

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Parameter Lower parameter value Higher parameter value Result
Cost difference LY difference QALY difference Cost difference LY difference QALY difference
Utility values1 -$Brz 8001 0,16 0,54 -$Brz 8001 0,16 0,27 Dominant
Medical costs1 -$Brz 7610 0,16 0,41 -$Brz 8392 0,16 0,41 Dominant
State-transition probabilities1 -$Brz 7851 0,12 0,37 -$Brz 8105 0,20 0,44 Dominant
Peginterferon-alfa-2a acquisition cost1 -$Brz 9938 0,16 0,41 -$Brz 6063 0,16 0,41 Dominant
Peginterferon-alfa-2b acquisition cost1 -$Brz 5254 0,16 0,41 -$Brz 10747 0,16 0,41 Dominant
Patient weight2 -$Brz 2769 0,16 0,41 -$Brz 13232 0,16 0,41 Dominant
SVR3 -$Brz 7902 0,16 0,39 -$Brz 8099 0,17 0,42 Dominant
Starting age4 -$Brz 8181 0,20 0,45 -$Brz 7788 0,14 0,37 Dominant
  1. Notes: 1Parameters were varied over the range of ±15%; 2Parameter was varied from 50 to 90 kg; 3Parameter was varied according to lower and upper limit values obtained from meta-analysis; 4Parameter was varied from 40 to 50 years old.